-5%
Tridopa (Levodopa + Carbidopa + Entacapone)
Indicated for the treatment of adult patients with Parkinson’s disease who experience end-of-dose motor fluctuations and are not adequately stabilized on levodopa/dopa decarboxylase (DDC) inhibitor therapy.
- Children: Safety not established.
- Elderly: No specific dose adjustment required.
- Hepatic impairment: Contraindicated in severe cases; caution with mild–moderate.
- Renal impairment: Use cautiously in severe cases, including dialysis patients.
Composition
Each film-coated tablet contains levodopa, carbidopa, and entacapone in a 1:4 ratio of carbidopa to levodopa plus 200 mg entacapone.
Tridopa 50: 12.5 mg carbidopa + 50 mg levodopa + 200 mg entacapone
Tridopa 75: 18.75 mg carbidopa + 75 mg levodopa + 200 mg entacapone
Tridopa 100: 25 mg carbidopa + 100 mg levodopa + 200 mg entacapone
Tridopa 125: 31.25 mg carbidopa + 125 mg levodopa + 200 mg entacapone
Tridopa 150: 37.5 mg carbidopa + 150 mg levodopa + 200 mg entacapone
Tridopa 200: 50 mg carbidopa + 200 mg levodopa + 200 mg entacapone
